Press release
direct/ AplaGen GmbH (DE) - Bayer Healthcare AG Animal Health and AplaGen sign a cooperation agreement
Baesweiler, 2006 September 25th,AplaGen GmbH and Bayer HealthCare AG Animal Health have signed an agreement for the evaluation, development and marketing of several therapeutic peptides from the AplaGen pipeline. The peptides will be used in the veterinary field only.
AplaGen will bring in its know how for development and synthesis of peptides as well as patented compounds and research capacities into the cooperation. Bayer will be responsible for preclinical and clinical development and worldwide marketing.
Dr. Franzpeter Bracht and Prof. Dr. Hans-Georg Frank, managing directors of AplaGen GmbH, welcome the closing of the agreement. "With Bayer HealthCare AG, we have found a strong leader of the industry as our partner."
AplaGen GmbH is a venture capital financed biotechnology company, located in Baesweiler, Germany. AplaGen GmbH is specialised on the evaluation and development of therapeutic peptides that can be used for different indications. AplaGen possesses a broad patent portfolio which is based on compounds as well as on peptide technologies.
Dr. Franzpeter Bracht
Dr. Silke Behne
AplaGen GmbH
Arnold-Sommerfeld-Ring 2
52499 Baesweiler
info@aplagen.com
Tel: +49 2401 805 570
Fax:+49 2401 805 574
The announcement distributed by directnews.
The issuer is solely responsible for the content of this announcement.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release direct/ AplaGen GmbH (DE) - Bayer Healthcare AG Animal Health and AplaGen sign a cooperation agreement here
News-ID: 11520 • Views: …
More Releases for Baesweiler
The market for transseptal access systems is expected to cross US$ 2 Bn by the e …
As per Persistence Market Research's latest revised industry analysis, the global transseptal access systems market was worth over US$ 771 Mn in 2020, and is projected to surge at a CAGR of 9.4% over the forecast period (2021-2031).
Surging obese population, increasing elderly population with greater risk of cardiac diseases, and rapid technological advancements in transseptal access systems are key factors contributing to significant increase in their sales. For example, the…
Global Transseptal Access Systems Market 2022 Segmentation, Demand, Growth, Tren …
As per Persistence Market Research's latest revised industry analysis, the global transseptal access systems market was worth over US$ 771 Mn in 2020, and is projected to surge at a CAGR of 9.4% over the forecast period (2021-2031).
Surging obese population, increasing elderly population with greater risk of cardiac diseases, and rapid technological advancements in transseptal access systems are key factors contributing to significant increase in their sales.
For example, the…
The Transseptal Access Systems Market To Witness An Exponential Satiation In The …
The Transseptal Access Systems Market is destined to reach US$ 771 Mn at a CAGR of 9.4% between 2021-2031. The healthcare vertical is moving the gadget-way. The current scenario is such that one need not make appointments for weeks/months for being treated. The real-time diagnosis and course of treatment could be possible. This simultaneous monitoring and treatment are bound to take the healthcare industry by storm in the next 10…
Mummert & Company exclusively advised the shareholders of chemagen Biopolymer-Te …
Munich, 14 February 2011 - Mummert & Company, an international and independent Corporate Finance advisor based in Munich, exclusively advised the shareholders of chemagen Biopolymer-Technologie AG on the sale to PerkinElmer, Inc. Effective immediately, chemagen is a wholly-owned subsidiary of PerkinElmer and will operate within PerkinElmer’s Emerging Diagnostics Business Entity.
chemagen offers magnetic bead based products for both research and diagnostics in academic, pharmaceutical, medical companies, commercial clinical labs…
AplaGen announces publication of a patent application for a novel technology tha …
AplaGen announces publication of a patent application for a novel technology that increases half-life of proteins in vivo
Baesweiler, Germany, December 7, 2009 - AplaGen GmbH announced today the publication of a patent application describing an innovative method for increasing the half-life of complex and/or multifunctional proteins in human and animal circulation in order to reduce infusion rates and increase patient quality of life. Large proteins that undergo high levels of…
chemagic 8 – a lab in a box
Baesweiler, March 31st 2009, the chemagen AG, Germany, introduces the chemagic 8, a customized solution for the entire laboratory workflow process. This particular lab in a box facilitates primary sample handling via Nucleic Acid isolation to diagnostics and storage with minimized hands on time in a fully automated way – that´s the chemagic AID.
The chemagic 8 combines 8 different features in an outstanding manner. The entire laboratory workflow processes…
